Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monofer vs Ferinject for Hypophosphatemia in RYGB Patients
NCT06350955Phase 4Recruiting
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms). Primary endpoint: Incidence of hypophosphatemia at Day 28. Started May 2024; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06350955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350955.